1-甲基-3-(三氟甲基)-1H-吡唑-4-磺酰氯 | 519056-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-3-(三氟甲基)-1H-吡唑-4-磺酰氯
• 中文别名: 1-甲基-3-三氟甲基-1H-吡唑-4-磺酰氯
• 英文名称: 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride
• 英文别名: 1-methyl-3-(trifluoromethyl)pyrazole-4-sulfonyl chloride
• CAS: 519056-67-8
• 化学式: C₅H₄ClF₃N₂O₂S
• mdl: MFCD04115368
• 分子量: 248.613
• InChiKey: HJFWSNIHZZKYIK-UHFFFAOYSA-N

物化性质

• 熔点：
  34 °C
• 沸点：
  302.5±42.0 °C(Predicted)
• 密度：
  1.73±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2933199090

SDS

Name:	1-Methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	519056-67-8

Section 1 - Chemical Product MSDS Name:1-Methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
519056-67-8	1-Methyl-3-(trifluoromethyl)-1H-pyrazo	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 14 29 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Reacts violently with water. Contact with water liberates toxic gas.
Causes burns.Water-reactive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Water Reactive. Material will react with water and may release a flammable and/or toxic gas.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. DO NOT USE WATER! Contact professional fire-fighters immediately.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Do not expose spill to water.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not allow water to get into the container because of violent reaction. Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale.
Use only in a chemical fume hood. Discard contaminated shoes. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Keep away from water. Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use explosion-proof ventilation equipment. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 519056-67-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 104 deg C @0.2mmHg
Freezing/Melting Point: 34 - 36 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4ClF3N2O2S
Molecular Weight: 248.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Reacts with water to form toxic fumes. Combines vigorously or explosively with water. Air sensitive. Moisture sensitive. Reacts with water to form hydrogen chloride, a toxic and corrosive gas.
Conditions to Avoid:
High temperatures, incompatible materials, dust generation, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines, water.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide, fluorine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 519056-67-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3096
Packing Group: II
IMO
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3096
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3096
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 14 Reacts violently with water.
R 29 Contact with water liberates toxic gas.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 519056-67-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 519056-67-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 519056-67-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-3-(三氟甲基)-1H-吡唑-4-磺酰氯 在 氨 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 以81%的产率得到1-methyl-3-(trifluoromethyl)pyrazole-4-sulfonamide
  参考文献：
  名称：

  [EN] MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
  [FR] MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR

  摘要：

  公式（I）的化合物及其药用盐，任何上述化合物的氘代衍生物，以及任何上述化合物的代谢物已被披露。还披露了包含这些化合物的药物组合物，使用这些药物组合物治疗囊性纤维化的方法，以及制备这些药物组合物的方法。还披露了化合物1及其盐和溶剂结晶形式。

  公开号：

  WO2018107100A1
• 作为产物：
  描述：

  1-甲基-3-三氟甲基-1H-吡唑 在 氯磺酸 、 氯化亚砜 作用下， 以 氯仿 为溶剂， 生成 1-甲基-3-(三氟甲基)-1H-吡唑-4-磺酰氯
  参考文献：
  名称：

  具有新型吡唑-4-磺酰肼支架的潜在琥珀酸脱氢酶抑制剂：分子设计、抗真菌评价和作用机制

  摘要：

  为了开发具有靶向琥珀酸脱氢酶（SDH）的独特分子支架的新型抗真菌剂，首先设计、合成了24 N'-苯基-1 H-吡唑-4-磺酰肼衍生物，并通过1 H NMR、13 C NMR 验证，高分辨率质谱（HRMS）和单晶X射线衍射分析。生物测定结果表明，目标化合物对四种供试植物病原真菌立枯丝核菌（R. solani）、灰葡萄孢、禾谷镰刀菌和黑链格孢具有高效、广谱的抗真菌活性。引人注目的是，复合B6被评估为抗立枯丝核菌的选择性抑制剂，其体外EC 50值 (0.23 μg/mL) 与 thifluzamide (0.20 μg/mL) 相似。相同条件下，200 μg/mL的化合物B6（75.76%）对立枯丝核菌的体内预防效果与thifluzamide（84.31%）大致相当。形态学观察探索表明，化合物B6能强烈破坏菌丝体形态，明显增加细胞膜的通透性，并显着增加线粒体数量。化合物B6还通过 IC 显着抑制

  DOI：

  10.1021/acs.jafc.3c00126

文献信息

• NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES
  申请人：Ackermann Jean

  公开号：US20110065707A1

  公开（公告）日：2011-03-17

  The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the significance given herein.

  本发明涉及式(I)的化合物以及其药学上可接受的盐，其中A1、A2、R1、R2、R3、R4、R5和R6具有本文中给出的含义。
• [EN] HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE HSL UTILES DANS LE TRAITEMENT DU DIABÈTE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011029808A1

  公开（公告）日：2011-03-17

  Compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1,R2 R3,R4 R5 and R6 have the significance given in claim 1. Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of illnesses, especially in the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity.

  化合物的化学式（I），以及其药学上可接受的盐可以用作药物组合物的形式，其中A1，A2，R1，R2，R3，R4，R5和R6具有权利要求1中给定的含义。本发明的目的是化学式（I）的化合物及其上述的盐和酯，以及它们作为治疗活性物质的用途，制造所述化合物的方法，中间体，含有所述化合物的药物组合物，含有所述化合物、其药学上可接受的盐或酯的药物，所述化合物、盐或酯的用途用于治疗或预防疾病，特别是用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症，以及所述化合物、盐或酯的用途用于生产用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症的药物。
• Discovery of <i>N</i>-[4-(1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors
  作者：Nis Halland、Friedemann Schmidt、Tilo Weiss、Joachim Saas、Ziyu Li、Jörg Czech、Matthias Dreyer、Armin Hofmeister、Katharina Mertsch、Uwe Dietz、Carsten Strübing、Marc Nazare

  DOI：10.1021/ml5003376

  日期：2015.1.8

  From a virtual screening starting point, inhibitors of the serum and glucocorticoid regulated kinase 1 were developed through a combination of classical medicinal chemistry and library approaches. This resulted in highly active small molecules with nanomolar activity and a good overall in vitro and ADME profile. Furthermore, the compounds exhibited unusually high kinase and off-target selectivity due

  从虚拟筛选的起点出发，通过结合经典药物化学和文库方法开发了血清和糖皮质激素调节激酶1抑制剂。这产生了具有纳摩尔活性并具有良好的整体体外和ADME谱的高活性小分子。此外，由于其刚性结构，这些化合物显示出异常高的激酶和脱靶选择性。
• HETEROARYLS AND USES THEREOF
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：US20150225422A1

  公开（公告）日：2015-08-13

  The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  本发明提供了一种具有以下化学式I的化合物： 及其药用可接受的盐，其中X、R1、R2、R3、R4、R5、L1、L2、m和n如规范中所述。这些化合物是VPS34的抑制剂，因此对于治疗增殖性、炎症性或心血管疾病是有用的。
• [EN] ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM<br/>[FR] N-SULFONYLGLYCINAMIDES ALPHA-SUBSTITUÉS ANTAGONISTES DU CCR10, COMPOSITIONS LES CONTENANT, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009142984A1

  公开（公告）日：2009-11-26

  Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.

  公开的是式（I）的化合物。其中，R1、R2、Ar和Cy如本文所定义，或其药学上可接受的盐。还公开了式（I）化合物的药物组合物，制备式I化合物的方法，以及使用式（I）化合物治疗与CCR10激活相关的疾病的方法。